Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats

Hypertension

Volumn 27, Issue 1, 1996, Pages 7-13

  Liu, Yun He ^a   Yang, Xiao Ping ^a   Sharov, Victor G ^a   Sigmon, David H ^a   Sabbah, Hani N ^a   Carretero, Oscar A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

angiotensin converting enzyme inhibitors; ischemia; kinins; myocardial infarction; myocardial reperfusion injury; nitric oxide; prostaglandins

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; BRADYKININ ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; INDOMETACIN; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RAMIPRILAT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0030049292     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.27.1.7     Document Type: Article

References (35)

1. Lucchesi BR. Complement, neutrophils and free radicals: mediators of reperfusion injury. Atzneimittelforschung. 1994;44:420-432.
2. Parratt JR. Cardioprotection by angiotensin converting enzyme inhibitors: the experimental evidence. Cardiovasc Res. 1994;28:183-189.
3. Lefer DJ. Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion. New Horiz. 1995;3:105-112.
4. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669-677.
5. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by un angiotensin-converting enzyme inhibitor. Circulation. 1982;65:40-48.
6. Ball SG, Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
7. Linz W, Schölkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol. 1986;8(suppl 10):S91-S99.
8. Martorana PA, Kettenbach B, Breipohl G, Linz W, Sehölkens BA. Reduction of infarct size by local angiotensin-converling enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 1990;182:395-396.
9. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol. 1993;21:996-1003.
10. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol. 1993;234:229-236.
11. 2 synthesis. Hypertension. 1989;13:754-758.
12. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension. 1991;18(suppl I):I-58-I-69.
13. Scicli AG. Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension. 1994;23:419-421. Editorial comment.
14. van Gilst WH, Tio RA, van Wijngaarden J, de Graeff PA, Wesseling H. Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia. J Cardiovasc Pharmacol. 1992;19(suppl 5):S134-S139.
15. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Rev. 1993;27:334-340.
16. Nolly H, Carretero OA, Scicli AG. Kallikrein release by vascular tissue. Am J Physiol. 1993;265:H1209-H1214.
17. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994;23:919-923.
18. van Wijngaarden J, Tio RA, van Gilst WH, de Graeff PA, de Langen CD, Wesseling H. Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: prostaglandins and bradykinin. Eur Heart J. 1990;11(suppl B):84-93.
19. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
20. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994;28:1301-1311.
21. Johnson G III, Tsao PS, Mulloy D, Lefer AM. Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J Pharmacol Exp Ther. 1994;252:35-41.
22. Nakanishi K, Vinten-Johansen J, Lefer DJ, Zhao Z, Fowler WC III, McGee DS, Johnston WE. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 1992;263:H1650-H1658.
23. Kanayama T, Kimura Y, Mizogami S. A new prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart. J Pharmacol Exp Ther. 1993;266:344-349.
24. Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992;20(suppl 9):S68-S73.
25. Hoffmann G, Düsing R. ACE-inhibition, kinins, and vascular PG12 synthesis. Eicosanoids. 1992;5(suppl):S60-S62.
26. Lucchesi BR, Werns SW, Fantone JC. The role of the neutrophil and free radicals in ischemic myocardial injury. J Mol Cell Cardliol. 1989;21:1241-1251.
27. Hori M, Gotoh K, Kitakaze M, Iwai K, Iwakura K, Sato H, Koretsune Y, Inoue M, Kitabatake A, Kamada T. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular circulation. Circulation. 1991;84:828-840.
28. Werns SW, Simpson PJ, Mickelson JK, Shea MJ, Pitt B, Lucchesi BR. Sustained limitation by Superoxide dismutase of canine myocardial injury due to regional ischemia followed by reperfusion. J Cardiovasc Pharmacol. 1988;11:36-44.
29. Linz W, Schölkens BA, Kaiser J, Just M, Qi BY, Albus U, Petry P. Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril. Cardiovasc Drugs Ther. 1989;3:873-882.
30. van Gilst WH, de Graeff PA, Wesseling H, de Langen CD. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol. 1986;8:722-728.
31. Parratt J. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res. 1993;27:693-702.
32. Schölkens BA, Linz W, König W. Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J Hypertens. 1988;6(suppl 4):S25-S28.
33. deGraeff PA, de Langen CDJ, van Gilst WH, Bel K, Scholtens E, Kingma JH, Wesseling H. Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. Am J Med. 1988;84(suppl 3A):67-74.
34. Bernier M, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms of protection by glucose and mannitol. Am J Physiol. 1988;254:H862-H870.
35. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of Superoxide by purified brain nitric oxide synthase. J Biol Chem. 1992;267:24173-24176.